Aramis Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aramisbio.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: A197 Ophthalmic SolutionDrug: Active ComparatorDrug: A197 Vehicle Control
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Aramis Biosciences, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT05238597
- Locations
- 🇺🇸
Aramis Site 113, Birmingham, Alabama, United States
🇺🇸Aramis Site 121, Garden Grove, California, United States
🇺🇸Aramis Site 120, Glendale, California, United States
News
No news found